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http://www.biomedcentral.com/1471-2091/13/8RESEARCH ARTICLE Open AccessPhosphatidylcholine formation by LPCAT1 is
regulated by Ca2+ and the redox status of the cell
Eric Soupene* and Frans A KuypersAbstract
Background: Unsaturated fatty acids are susceptible to oxidation and damaged chains are removed from
glycerophospholipids by phospholipase A2. De-acylated lipids are then re-acylated by lysophospholipid
acyltransferase enzymes such as LPCAT1 which catalyses the formation of phosphatidylcholine (PC) from lysoPC and
long-chain acyl-CoA.
Results: Activity of LPCAT1 is inhibited by Ca2+, and a Ca2+-binding motif of the EF-hand type, EFh-1, was identified
in the carboxyl-terminal domain of the protein. The residues Asp-392 and Glu-403 define the loop of the hairpin
structure formed by EFh-1. Substitution of D392 and E403 to alanine rendered an enzyme insensitive to Ca2+, which
established that Ca2+ binding to that region negatively regulates the activity of the acyltransferase amino-terminal
domain. Residue Cys-211 of the conserved motif III is not essential for catalysis and not sufficient for sensitivity to
treatment by sulfhydryl-modifier agents. Among the several active cysteine-substitution mutants of LPCAT1
generated, we identified one to be resistant to treatment by sulfhydryl-alkylating and sulfhydryl-oxidizer agents.
Conclusion: Mutant forms of LPCAT1 that are not inhibited by Ca2+ and sulfhydryl-alkylating and –oxidizing agents
will provide a better understanding of the physiological function of a mechanism that places the formation of PC,
and the disposal of the bioactive species lysoPC, under the control of the redox status and Ca2+ concentration of
the cell.
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The oxygen carrying function of the red blood cell (RBC)
leads to the generation of reactive oxygen species in the
cell, and despite an intricate system of antioxidants, free
radical damage of un-saturated acyl chains of glyceropho-
spholipids occurs continuously. These oxidized acyl chains
lead to a breach in normal membrane lipid organization
and need to be replaced to maintain integrity of the
membrane. The oxidized phospholipids (PL) are de-
acylated by phospholipase A2 (PLA2) action [1-4], and re-
acylation of the resulting lysophospholipid (lysoPL) is
achieved by a two-step process. Fatty acids are activated to
acyl-CoAs by membrane-bound long-chain acyl-CoA
synthetases (ACSL) [5-7] and the acyl group of acyl-CoA
is then transferred to lysoPL by acyl-CoA:lysoPL acyltrans-
ferase (LPLAT) enzymes [8-11]. This repair mechanism is
also known as the Lands’ cycle [8,12].* Correspondence: esoupene@chori.org
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distribution, and reproduction in any mediumPhosphatidylcholine (PC) is the most abundant glycer-
ophospholipid in membranes [13], with unsaturated acyl
chains, mainly found at the sn-2 position. Repair of oxi-
dized PC and re-acylation of the lysoPC in RBC pro-
ceeds rapidly by utilizing fatty acids that are taken up
from plasma, and the action of ACSL and LPCAT in the
plasma membrane [14]. We previously identified ACSL6
as the acyl-CoA synthetase in the RBC membrane and
LPCAT1 as the acyl-CoA:lysoPC acyltransferase [7,15-
17]. LPCAT1 is also the enzyme for the re-acylation of
PC in alveolar type II cells [18,19]. Furthermore,
LPCAT1 might play an essential role in production of
lipid surfactant in lung [20,21], and in regulating the
level of inflammatory lipids, such as lysoPAF and lysoPC,
in the retina [22,23]. LPCAT1 also appears to mediate
O-palmitoylation of histone H4 in the nuclei of lung epi-
thelial cell [24].
LPCAT1 does not require Ca2+ for activity [16,19]
and was reported as a Ca2+-independent member of
the LPCAT family of enzymes [25-27]. Activity ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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defined as a Ca2+-dependent member of the LPCAT
family [25-28]. However, two EF-hand motifs, folding
into hairpin structure coordinating Ca2+ [29-32], are
predicted in both LPCAT1 and LPCAT2 [16,18,28]. Al-
though, we have confirmed that Ca2+was not required
for activity of LPCAT1, i.e. Ca2+-independent in [25],
we have established that Ca2+was in fact inhibitory on
the LPCAT1 activity [16]. At the millimolar Ca2+ con-
centration values found in plasma [33], acylation rate
of LPC by LPCAT1 was reduced and showed dependency
to Ca2+ concentration [16]. Thus, as it is the case for
LPCAT2, Ca2+ also regulates the activity of LPCAT1.
These observations led us to investigate the role of the
predicted EF-hand motifs in Ca2+-binding.
LPCAT1 activity is also sensitive to treatment by
sulfhydryl-modifier agents, such as the alkylating thiol re-
ductant N-ethyl maleimide (NEM) [34]. Cursory observa-
tion indicated that of the 12 cysteines of LPCAT1, Cys-
211 found at the +1 position of motif III, 207PEGT210,
could be conserved among acyltransferase forms that are
sensitive to NEM and may be responsible for their sensi-
tivity to this agent [34]. This residue was also proposed to
define the ‘motif 3-cysteine acytransferases’ sub-family of
LPLAT enzyme and to be crucial for catalysis [34].Figure 1 Cartoon representation of LPCAT1 (A) and alignment of Mot
of LPCAT1 enzyme (GenBank accession number: NP_663351), conserved am
transmembrane spanning segments (TM1, TM2, TM3, TM4) [16] are shown
model is only representative of a prediction that would support orientation
membrane surface) with exposure of the two predicted EF-hand motifs on
6 most conserved residues underlined, is shown. The 12 cysteines are also
mouse Agpat and Lpcat families. The arginine and a cysteine residue found
enzymatic activity of the protein is indicated on the right. Substrate specifi
predicted to be LPAAT enzyme. Agpat7 is now annotated as Lpcat4. The a
annotated as LCLAT1, was mis-identified by Agarwal et al. [43] as a new m
been removed from database. Not shown is LPCAT3, formerly annotated a
other LPCAT members [44,45].However, the role of Cys-211 in the sensitivity to NEM
and in catalysis was never tested since even the substitu-
tion of Cys-211 to the arginine residue present at the end
of motif III of LPAAT enzymes [35], rendered an inactive
C211R form [34]. Similarly, substitution of Arg-181 of
motif III of the human LPAAT enzyme AGPAT1 to sev-
eral other residues rendered inactive forms [36].
We report that the EFh-1 motif of LPCAT1 is a func-
tional Ca2+-binding site and that Cys-211 is not essential
for activity of LPCAT1. Up to six cysteines residues, in-
cluding Cys-211, are responsible for the decrease activity
of the enzyme after treatment by NEM and diamide.
The sensitivity of LPCAT1 activity to thiol damage and
to Ca2+ binding to the EFh-1 site establishes that acyl-
ation of the most abundant phospholipids of the cell
membranes is under the control of the redox status and
Ca2+ concentration of the cell.
Results
Role of Asp-392 and Glu-403 residues in calcium
inhibition
We previously determined that activity of mouse
LPCAT1 (formerly known as Aytl2) and of LPCAT2
(Aytl1) were inhibited in presence of millimolar concen-
tration of calcium chloride. Addition of EDTA to theif III residues of some LPLAT members (B). (A) Motifs I, II, III and IV
ong LPLAT enzymes, are indicated in light grey. Four predicted
in black. The topology of LPCAT1 is not know and the presented
of all 4 conserved motifs to the cytosolic side (or near the cytosolic
the cell surface. The amino acid sequence of the EFh-1 motif, with the
indicated. (B) Amino acid alignment of motif III of members of the
at the + 1 position of the PEGT motif are indicated. When known,
city of Agpat4 and Agpat5 is not known but the two members are
cyl-CoA:lysoCardiolipin acyltransferase 1 protein (ALCAT1) [42], currently
ember of the AGPAT family, AGPAT8. The annotation for Agpat8 has
s membrane-bound O-acyltransferase 5 (Mboat5), which differs from
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some membranes [9,37], physiological intracellular Ca2+
concentration (< 0.1 mM) had no effect on activity. The
activity of third member Aytl3, currently annotated as
LPCAT4, was not affected by the presence of Ca2+. A pair
of Ca2+-binding sites of the EF-hand type was predicted
at the carboxy-terminal extremity of LPCAT1 and
LPCAT2 but not of LPCAT4 ([16] and Figure 1A). Of the
two motifs, EFh-1 was the best match to a consensus se-
quence (392DxSxGxExDx2E
403), as it contains the crucial
first aspartate and last glutamate residues, which are ne-
cessary to coordinate the divalent cation to the hairpin
structure [31,38-41].
Asp-392 and Glu-403 were substituted by site-directed
mutagenesis to alanine. The two single-substituted re-
combinant protein, D392A and E403A, and the double
mutant form, D392A/E403A, were produced and their ac-
tivities in absence and presence of an inhibitory Ca2+
concentration of 10 mM [16] were determined. All three
mutants proteins were active and their activity rate was
70 to 80% of LPCAT1 activity (Figure 2A). Thus, Asp-
392 and Glu-403, which are not conserved in LPLAT
enzymes, are dispensable for activity. Activity of the mu-
tant forms was less sensitive to presence of Ca2+ than
LPCAT1. In particular, activity of the double mutant
form D392A/E403A was unaffected even in presence of
10 mM calcium chloride (the highest concentrationFigure 2 Role of D392 and E403 in Ca2+-inhibition of LPCAT1 activity. A
changed by site-directed mutagenesis to an alanine, and the activity of the
determined. Activity measurements were performed with 5 μM [14C]-C18:1-C
Acylation rates were calculated between 0 and 8 min. The standard deviati
separation by thin-layer chromatography, the amount of [14C]-PC formed d
Experimental section) and the activity rate values are calculated as PC form
performed with LPCAT1 and the 3 mutant enzymes. Values obtained for th
with LPCAT1. (B) Activity of LPCAT1 and of the three mutant forms was de
chloride. Activity rates were calculated as described above. The ratio of the
its absence for each protein is reported as fold inhibition. Note that a ratio
of Ca2+ was identical.tested), which resulted in a 4-fold inhibition of activity
of LPCAT1 (Figure 2B). These findings establish that
EFh-1 motif is a functional Ca2+-binding site. It was
reported that LPCAT1 does not require Ca2+ [19,25-27],
These data show that the activity of LPCAT1 is regu-
lated by high Ca2+-concentrations.
Sensitivity of LPCAT1 to thiol alkylation and oxidation
LPCAT1 has 12 cysteine residues and the activity of
human LPCAT1 was shown to be inhibited by the thiol
alkylating agent N-ethylmaleimide (NEM) [34]. Sensitiv-
ity of the LPCAT1 acyltransferase activity to oxidation
of thiol groups of cysteines was determined after incuba-
tion with either NEM or the cross-linker agent diamide
at a concentration of 0.5 mM for 30 minutes. Subse-
quently the mixtures were diluted 20-fold and activity
was measured. Under these conditions, LPCAT1 activity
was reduced to 20-25% as compared to the activity after
incubation with buffer (Figure 3). In addition, protein
was also labeled by a biotinylated-version of NEM, 3-
maleimidylpropionyl-biocytin (MPB), which confirmed
the sensitivity of some sulfhydryl groups to the alkylating
agent (see below). Treatment of LPCAT1 with 20 mM
DTT had little effect on activity suggesting that in the
membrane, cysteines important for activity were in a
reduced state (Figure 3A, first filled bar). Diamide generates
disulfide bonds between cysteines whereas NEM alkylatessp-392 and Glu-403 of the predicted EFh-1 motif of LPCAT1 were
three mutants enzymes, D392A, E403A and D392A,E403A was
oA in the presence of 20 μM LPC at 37°C with 1 μg of proteins.
on of 3 different measurements is indicated as error bars. After
uring the reaction was quantified by phosphoimaging (see the
ed/ μg of protein per min. (A) Measurement of the activity rates was
e mutant forms are reported relative to the activity rate value obtained
termined in the absence and in the presence of 10 mM calcium
value obtained in presence of Ca2+ relative to the value obtained in
value of 1 indicates that the activity rate in presence and in absence
Figure 3 Effect of sulfhydryl-alkylation and of disulfite bond formation on activity. Measurement of LPCAT1 activity was performed as
described in legend of Figure 2. The standard deviation of at least 3 different measurements is indicated as error bars. (A) Treatment with
diamide (0.5 mM) and N-ethylmaleimide (0.5 mM) were performed for 30 min before assaying acyltransferase activity. In some reactions, DTT was
added at a concentration of 20 mM after treatment with diamide or NEM, and mixtures were incubated for another 10 min. Concentrations of
the reagents were reduced 20-fold by dilution into the acyltransferase reaction mixture to assay the activity of the treated enzyme. Before
assaying their activity, control samples were incubated for the same period of time and under the same condition in absence of diamide, of NEM
and of DTT. The activity rate value obtained in absence of any of these chemicals (buffer without DTT) was arbitrary set at 1 and all others values
were calculated relative to it. (B) Activity rate of LPCAT1 (circle) and of mutant C211T (triangle) were measured after treatment by different
concentrations of NEM, as described above. For each protein, the value obtained in absence of treatment was set at 1 and values obtained after
treatment were calculated relative to it. The activity rate ratio of the mutant form C211T, C(216,314,443,501,514)A obtained without and after treatment
with 1 mM NEM is also reported (cross symbol).
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DTT fully restored activity of a diamide-treated enzyme
mixture but the covalent modification of these cysteines by
NEM could not be reversed by DTT treatment (Figure 3A).
Cys-211 is not essential for activity
In order to determine the role of Cys-211 (Figure 1A) in
catalysis and in sensitivity of the enzyme to NEM treat-
















Cys-530 to Alathe Cys-211codon and screened the collection of clones
for active mutant forms (Table 1). As observed previ-
ously [34], we confirmed that substitution of Cys-211 to
most other residues greatly reduced activity of LPCAT1,
resulting in enzymes with low or no detectable activity
(Figure 4). However, one mutant form, C211T, could pro-
duce as much PC as LPCAT1 (Figure 4A), with an activ-
ity rate of about 60% of LPCAT1 (Figure 4B). Thus, Cys-
















Figure 4 Cys-211 is not essential to the acyltransferase reaction. A collection of mutant forms in which C211 was changed to E, W, P, Y, G, Q,
V, L, F and T was obtained by random mutagenesis of the Cys-211 codon. In addition, site-directed mutagenesis was performed to change C211
to S and R. Clones were tested for production of the mutant protein [panel A, top gel] and for their lysoPC-acyltransferase activity [panel A,
bottom gel]. (A) Top gel: Proteins were separated on a 12% gel SDS-PAGE and stained with coomassie blue. Molecular mass standard (Precision
Plus Protein Standard, Bio-Rad) is shown on the right (last lane). Position of the LPCAT1 protein (lane C) and of the mutant forms (S, R, E, W, P, Y,
G, Q, V, L, F, T) is indicated with a black arrow on the left. Note the absence of LPCAT1 protein in the control sample prepared from cells
containing the empty expression vector (lane vector). Production and position of the proteins were confirmed by Western blot detection of the
hexa-histidine tags with an anti-histidine antibody (India-His, Pierce). (A) Bottom gel: Detection of the lysoPC-acyltransferase activity was
performed with 5 μM [14C]-C18:1-CoA in presence of 20 μM LPC at 37°C with a 20 min incubation and with 10 μg of proteins, which represent 10
time more enzyme than the amount used to calculate activity rate (1 μg). Products were separated on silica plates and detected by
phosphoimaging. Pure [14C]-PC was used as a migration standard, last lane on the right and position of [14C]-PC is indicated on the left with an
arrow. Note the absence of the product [14C]-PC in the vector lane (left). (B) Activity rate measurements were performed as described in legend
of Figure 2. LPCAT1, Rates of C211R mutant (see text) and of the C211 mutant forms able to form [14C]-PC, as shown on panel A, were determined.
Values obtained for the mutant forms are reported relative to the activity rate obtained with the LPCAT1 enzyme (dubbed C211). Amino acid
sequence of motif III is shown. The standard deviation of at least 3 different measurements is indicated as error bars.
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The rate of LPCAT1 activity is dependent on the con-
centration of NEM and was reduced almost ten-fold
after treatment with 1 mM (Figure 3B, circle symbols).
Although, the C211T protein was not as sensitive as
LPCAT1 to NEM, it was still inhibited by this sulfhydryl
reagent (Figure 3B). At a NEM concentration of
0.25 mM, the C211T enzyme was inhibited nearly as
much as LPCAT1 (2.5-fold versus 3-fold). However,
whereas treatment with higher NEM concentration
(from 0.25 to 1 mM) decreased the activity rate of
LPCAT1 another 3-fold, it had no additional inhibitory
effect on the C211T form. Similarly, this mutant form
was also less sensitive to inhibition by diamide
(Figure 5A) as compared to LPCAT1. Thus, removal of
Cys-211 had a protective effect towards the treatment by
sulfhydryl-oxidizer and alkylating agents, but the bi-
phasic pattern of the NEM titration of C211T activity also
indicated that other cysteines altered catalysis after at-
tack by the alkylating agent (Figure 3B). In support of
these findings, we found that the C211T protein was stilllabeled by the biotinylated alkylating agent maleimidyl-
propionyl-biocytin (MPB) (see below).
Role of cysteine residues in sensitivity to sulfhydryl
modifier agents
To identify other cysteine residues conferring sensitivity
to NEM and diamide, we performed alanine scanning of
the 11 cysteines still present in the active mutant form
C211T. The mutants were generated by a multi-sites-
directed mutagenesis approach to create a collection of
different proteins with an increased probability to find
active forms among them (see the Experimental section).
The collection is listed in Additional file 2: Table S1.
Protein expression, acyltransferase activity and sensitivity
to sulfhydryl modifier agents of the mutant forms are
shown in Figure 5, Figure 6 and Additional file 1: Figure
S1.
The majority of the mutants displayed a very low activ-
ity (Figure 6A and Additional file 1: Figure S1). However
in addition to the C211T form described above, five
mutants missing 2 to 6 cysteines were obtained that
Figure 5 Cysteine residues implicated in sensitivity to sulfhydryl-modifier agents. Activity rate measurements were performed as described
in the legend of Figure 2. Treatments with NEM and diamide were performed as described in legend of Figure 3. The standard deviation of at
least 3 different measurements is indicated as error bars. Results obtained for mutant forms that are not shown here (clone FK480, FK481), are
presented in Additional file 1: Figure S1A. (A) Activities of LPCAT1, C211T and of the mutant C211T, C(216,314,443,501,514)A in absence (filled square)
and after treatment by 1 mM NEM (crosses) or by 1 mM diamide (triangles) are shown. Values are reported as amount of PC formed per μg of
proteins in function of time. (B) Activity rates were measured as shown in panel A. For each protein, the value obtained in absence of treatment
(buffer) was set at 1 and values obtained after treatments were calculated relative to it.
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and Figure 6). These 6 active proteins establish that Cys-
211, 216, 314, 443, 501 and 514 are not essential to theFigure 6 Activity of Cysteine substitution mutant enzymes. Alanine sc
performed to generate a collection of C-to-A mutant forms. The list of clon
Clones were tested for production of the mutant protein (top gel) and for
legend of Figure 4A. The row number (4 to 17) indicates the clone listed (r
measurements were performed as described in the legend of Figure 4B. In
with significant acyltransferase activity as shown on panel A, [C211T C443A, r
C(216,314,443,501,514)A, row 7], were determined. Protein expression and activit
Values are reported relative to the activity rate obtained with LPCAT1 enzy
indicated as error bars.acyltransferase reaction (Additional file 2: Table S1). We
could not identify a pattern and determine which cyst-
eine, if any, was essential for activity. As observed foranning of the 11 cysteines present in the active form C211T was
es and their mutations are presented in Additional file 2: Table S1. (A)
their lysoPC-acyltransferase activity (bottom) as described in the
ow 4 to 17) in Additional file 2: Table S1. (B) Activity rate
addition to LPCAT1 and C211T, rate values for the mutant enzymes
ow 4], [C211T C(314,457)A, row 5], [C211T C(216,443,514)A, row 6] and [C211T
y of the form C211T, C501A are presented in Additional file 1: Figure S1.
me. The standard deviation of at least 3 different measurements is
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and resulting in inactive mutant forms, alanine substitu-
tion of other non-essential cysteines could render mutant
proteins with low activity due to structural alterations and
defects. Among the active mutants, the form lacking all
six cysteines mentioned above, C211T C(216,314,443,501,514)A,
was the most active and had a higher activity rate than
LPCAT1 (Additional file 2: Table S1 and Figure 6). The
other active forms displayed 50 to 150% of the activity of
LPCAT1 (Figure 6). With one exception, all active forms
were as sensitive to NEM and diamide treatment as was
C211T (Figure 5B and Additional file 1: Figure S1). Activ-
ity of the mutant C211T C(216,314,443,501,514)A was not
affected by treatment with either reagent (Figure 5). Even
under condition resulting in 80 to 90% inhibition of the
activity of LPCAT1, this mutant protein was still fully ac-
tive. Moreover, it reproducibly displayed greater activity
after treatment by diamide (Figure 5B, last bars).
Cysteines labeling by maleimidylpropionyl-biocytin
reagent
LPCAT1, C211T and a mutant form lacking all 12
cysteines (Cys12-) were purified (Additional file 3: Figure
S2) and then, exposed to maleimidylpropionyl-biocytin,
which can be detected with streptavidin (see Experimen-
tal section). The Cys12- protein was not modified by
MPB indicating the cysteine-requirement of this alkylat-
ing reagent (last lane, Figure 7A). However, bothFigure 7 Detection of sulfhydryl-modification of cysteine mutant form
cells producing LPCAT1 and several Cysteine mutant forms (panel B) were
Experimental section. (A) Proteins were purified and 2 μg aliquots were lab
stopped by quenching the unreacted MPB reagent with 25 mM DTT. Labe
and visualized by coomassie blue staining (bottom gel). Proteins were tran
streptavidin, which interacts with the biotin group of MPB. Molecular mass
microsomal proteins as shown in Figure 4A and Figure 6A were labeled wi
LPCAT1 and mutant forms were affinity-purified. Proteins were separated o
with HRP-conjugated streptavidin (top membrane) or with a HRP-conjugat
cysteines (Cys12-) was detected (last lane, bottom) but was not labeled (last
was not inhibited by treatment with NEM , lane NEMr, was labeled by MPB
FK614 (see Additional file 2: Table S1) are shown in lane Cys7-, Cys8-, Cys9-,
indicated on the right.LPCAT1 and the C211T protein were labeled by MBP
(Figure 7A). These results confirmed the sensitivity of
more than one -SH group to NEM and thus, that several
cysteine residues, not only Cys-211, are the target of
these alkylating agents.
To define the role of the 12 cysteines in the alkyl-
ation reaction, mutant forms embedded in the mem-
brane, and presumably correctly folded, were exposed
to MPB. Following treatment and quenching with
excess amount of DTT, membrane proteins were
dissolved in CHAPS and mutant forms were purified,
as described in the Experimental section. The label
was revealed with streptavidin and the different forms
(unlabeled and labeled) were detected with an antibody
reacting against the hexa-histidine tag. Unexpectedly,
all 12 cysteines were alkylated and all mutant forms
containing at least one cysteine residue were labeled
by MBP (Figure 7B). Even the mutant enzyme C211T C
(216,314,443,501,514)A, whose activity was not affected by
treatment with NEM, was also labeled by MPB
(Figure 7B, lane NEMr). This result established that al-
kylation of some of the 6 cysteines still present in
C211T C(216,314,443,501,514)A were susceptible to alkyl-
ation and that their alteration had no effect on activity
of the enzyme (Figure 5B, last bars). It cannot be ruled
out that substitution of one, or more, cysteine resulted
in a structural change and the exposure of thiol groups
that were otherwise protected from labeling in thes. Purified proteins (panel A) and membrane fractions obtained from
treated with maleimidylpropionyl-biocytin (MPB) as described in the
eled with 100 μM of MPB protected from light. Reactions were
led and unlabeled proteins were separated on a 12% gel SDS-PAGE,
sferred onto PVDF membranes and blotted with HRP-conjugated
standard is shown on the right. (B) An equivalent of 25 μg of
th 100 μM MPB. After quenching with DTT, hexa-histidine tagged
n a 12% gel SDS-PAGE, transferred onto PVDF membranes and blotted
ed anti-histidine antibody (bottom). The mutant form lacking all 12
lane, top). The mutant form C211T, C(216,314,443,501,514)A, whose activity
. Results obtained with clone FK605, FK607, FK606, FK609, FK613 and
Cys10-, Cys11- and Cys12-, respectively. Molecular mass standard is
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C211T C(216,314,443,501,514)A enzyme established that
modification of LPCAT1 by alkylating agents is due to
attack of several cysteine residues that are not essential
for catalysis.
Discussion
In the calmodulin superfamily of Ca2+-binding proteins,
repeats of EF-hand motifs are often present in tandem
but few forms, such as the members of the S100 family,
contain a single pair of sites [39]. Member 1 and 2 of
the LPCAT family have two EF-hand motifs and thus,
belong to the S100 Ca2+-binding protein family
[16,18,28]. In the helix-loop-helix structure of such
calcium-binding sites, the loop coordinates the divalent
cation to seven oxygen atoms of semi-conserved resi-
dues [30-32,38]. There is a great variability of sequence
but the first and last residues of the loop are almost always
an aspartate and glutamate, respectively. The EFh-2 motif
of LPCAT1 is lacking these two important residues [16]. It
was suggested that the EF-hand motifs of LPCAT1 could
be structurally different with divergent functions as com-
pared to those present in LPCAT2 [25]. Our findings es-
tablish that activity of LPCAT1 is controlled by Ca2+
and that the EFh-hand motifs of LPCAT1 represent ac-
tive Ca2+-binding sites, as in LPCAT2.
The residue found at the +1 position of motif III of
LPLAT was thought to confer preference to different ac-
ceptor species (lysoPA, lysoPC or lysoCardiolipin) for
acylation with acyl-CoAs. With the identification of
many more members of the large LPLAT family, it now
appears that presence of a cysteine, arginine or aspartate
residue at that position does not define specificity to the
substrate (Figure 1B). Nevertheless, these residues must
play some role in catalysis since their substitution often
rendered inactive forms. As shown previously by Shi-
mizu, T and colleagues [34], we confirmed that Cys-211
of LPCAT1 could not be replaced by an arginine residue.
An arginine is present at that position in the three char-
acterized LPAAT enzymes (AGPAT1, AGPAT2 and
AGPAT3) (Figure 1B). Substitution of Cys-211 to many
other residues rendered inactive forms. Substitution of
Arg-181 of AGPAT1 to an alanine or a lysine also ren-
dered inactive enzymes [36]. Thus, these residues are
important for activity of LPLAT enzymes but activity of
the C211T mutant of LPCAT1 established that contrary
to previous report [34], Cys-211 is not essential for ca-
talysis. In addition, removal of Cys-211 did reduce, but
did not eliminate sensitivity to NEM. It also did not pre-
vent labeling of the protein by MPB. These results dem-
onstrate that Cys-211 is also not crucial for the
sensitivity of LPCAT1 activity to alkylating agents. The
C211T C(216,314,443,501,514)A enzyme was unaffected by
treatment with diamide and NEM suggesting that acombination of several cysteines among Cys-211, Cys-
216, Cys-314, Cys-443, Cys-501 and Cys-514 confer sen-
sitivity of the acyltransferase reaction to these reagent
but that none of these residues is essential for catalysis.Conclusions
The RBC is exposed to high oxidant stress from the cyto-
solic side due to the hemoglobin-mediated transport of
oxygen and is exposed to high concentrations of Ca2+ in
plasma [33,46,47]. Both an increase in cytosolic calcium
and oxidant stress lead to a loss of the membrane
phospholipid asymmetry with the exposure of phosphati-
dylserine and removal of the damaged cells. The sensitiv-
ity of the de-acylation/re-acylation repair cycle suggests
that the integrity of their membrane will also be compro-
mised. In hemoglobinopathies, such as sickle cell disease
and thalassemia, the presence of damaged RBCs in the
circulation plays a significant aggravating role in the vas-
culopathy that characterizes these disorders. Thus, regula-
tion of LPCAT1 activity might contribute to the removal
of damaged-RBCs from the circulation and could repre-
sent a mechanism for the dismissal of stressed cells in
other tissues.Methods
Materials
[1-14C]C18:1-CoA (55.0 mCi/mmole) was from from
Amersham Corp., (Arlington Heights, IL, U.S.A) and 1
acyl-lysoPC from Avanti Polar Lipids, Inc. (Alabaster,
AL, U.S.A). TLC silica plates were obtained from Ana-
ltech. Inc. (Newark, DE, U.S.A). N-Ethylmaleimide
(NEM) and diamide were from Sigma-Aldrich, Inc. (St.
Louis, MO, USA). Na-(3-maleimidylpropionyl)biocytin
(MPB) was from Invitrogen. All other compounds used
were reagent grade.DNA manipulations
Cloning of mouse LPCAT1 was previously reported
[16]. Full-length cDNA was cloned in pET28a vector
(Novagen), with a unique in-frame hexahistidine tag
at the N-terminus, to yield plasmid pFK192. Site-
directed mutagenesis experiments were performed
with the QuikChange Multi Site-directed Mutagen-
esis kit (Stratagene) according to the manufacturer
instruction. Primers were designed with the Quik-
ChangeW Primer Design Program (Stratagene) and
are listed in Table 1. The presence of the intended
nucleotide change(s) and the absence of unwarranted
mutations were verified by full-length sequencing of
the constructs. Position of the amino acid residues is
given relative to the full-length mouse LPCAT1
protein NP_663351 (534 amino acids).
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Expression of (His)6-LPCAT1 was previously reported
[16]. Production of (His)6-LPCAT1 was obtained by
growing E. coli strain, Rosetta™ 2(DE3) transformed with
the different recombinant constructs in presence of
500 μM of IPTG for 3 hours. Cells were collected, dis-
rupted and membrane fractions were obtained by centri-
fugation as previously described [16]. Samples were
stored at −80°C in Tris–HCl 0.2 M pH 7.4 with 10% gly-
cerol. For analysis, protein samples were denatured for
20 min at 37°C in SDS-PAGE loading buffer and sepa-
rated on SDS-PAGE 12% gel. Proteins were visualized by
staining (GelCode Blue stain reagent, Pierce) and recom-
binant (His)6-LPCAT1 proteins were detected with a
commercial HRP-conjugated anti-histidine antibody
(INDIA-HisProbe-HRP antibody, Pierce), diluted a thou-
sand fold. HRP detection was performed with Super-
Signal West Pico Chemiluminescent kit (Thermo Fisher
Scientific Inc., Rockford, IL).
Measurement of LPCAT activity in isolated E. coli
membranes
Incorporation of [14C]acyl-CoA into egg lysoPC by re-
combinant LPCAT1 protein in E. coli membranes was
determined as previously described [16]. Reactions were
performed in glass tubes at 37°C in a shaking water bath,
in 200 μl of (Tris–HCl 20 mM, pH 7.4; Tween-20
0.8 mg/ml) containing 20 μM lysoPC and 5 μM [14C]
acyl-CoA. Reactions were initiated by addition of 1 to
15 μg of membrane protein fractions and incubated
from 0 to 8 min. Three to four time points, in triplicate,
were used to determine the PC formation rate by
LPCAT1 enyzmes. Preliminary experiments were per-
formed to determine the correct amount of microsomes
necessary to obtain a linear dependency of PC formation
by the different mutant forms (Additional file 2: Table
S1). For forms with very low activity up to 15 μg of
microsomes were used in each reaction. Control experi-
ments were performed with membrane fractions
obtained from E. coli strains transformed with the empty
pET28a vector. Under our growth condition, no detect-
able E. coli acyl-CoA: 1-acyl-lysoPC acyltransferase activ-
ity was detected (first lane of Figure 4A and Figure 6A).
Reactions were stopped by the addition of 200 μl of
CHCl3:MeOH:12 N HCl (40:40:0.26, v/v) and vigor-
ous vortexing. Phases were separated by centrifuga-
tion at 1,000 g for 5 min and the lipid-containing
chloroform phase was dried down under N2, and
dissolved by vortexing in 20 μl of CHCl3:MeOH (2:1,
v/v). Samples were applied to TLC silica plates and
developed with chloroform/methanol/acetic acid/0.9%
NaCl (100:50:16:5, v/v). TLC plates were air-dried
for 20 min and exposed to a PhosphoImager screen
(Storm 840, Molecular Dynamics). Quantification ofPC formation was performed with ImageQuant soft-
ware subtracting the plate background.
To determine the effect of divalent cations on LPCAT1
activity the rate of [14C]PC formation was measured in ab-
sence or presence of 10 mM calcium chloride in the incu-
bation mixture. Assays were performed in triplicate. The
samples to be compared were applied and developed on
the same plate. The relative activity rate is expressed as
the ratio of the rates in the presence compared to the rate
in the absence of the divalent cation. To determine the ef-
fect of N-ethylmaleimide and of diamide on LPCAT1 ac-
tivity membrane fractions were incubated with the
chemical for 30 minutes on ice in Tris–HCl 20 mM pH
7.4. The incubation in 10 μl, was followed by a 20 times
dilution into the reaction mixture (200 μl). In some assays,
membrane samples were first treated with 0.5 mM NEM
or diamide and one half of the mixture was then incubated
with 20 mM dithiothreitol (DTT) for 20 min at room
temperature. Samples were then assayed for LPCAT activ-
ity as described above.




Cells were grown and proteins were induced as
described above. Proteins were purified using His Gravi-
Trap and His buffers kit of Amersham (GE Healthcare)
in presence of 1% CHAPS. Frozen cell pellets obtained
from 1 liter of culture were thawed on ice in 10 ml of
breakage buffer (20 mM Sodium Phosphate pH 7.4,
0.5 M NaCl, 20 mM Imidazole, 1 mM PMSF and 10%
glycerol). Cells were disrupted with a French-press cell
at 12,000 psi. The resulting lysate was cleared by centri-
fugation at 16,000 g for 20 min at 4°C. ß-
Mercaptoethanol was added to a final concentration of
5 mM. Membranes were collected by centrifugation at
100,000 g for 1 hr at 10°C. The pellet was slowly sus-
pended in 1 ml of breakage buffer containing 2%
CHAPS with a stir bar on a magnetic plate for about
30 min. One ml of breakage buffer was added, and 5 ml
of breakage buffer containing 1% CHAPS was then
mixed to obtain 7 ml of sample in BB with 1% CHAPS.
It was loading on pre-washed and equilibrated Nickel
column. The sample was passed 2 to 3 times on the col-
umn to improve binding of the protein. The column was
washed with 20 volume of breakage buffer containing
1% CHAPS. Stepwise elution was performed with 3 ml
BB containing 1% CHAPS and 50 mM, 200 mM and
500 mM imidazole. As shown on Additional file 3: Fig-
ure S2, LPCAT1 and mutant forms were detected in the
third elution with few contaminant proteins.
MPB labeling and detection
Na-(3-maleimidylpropionyl) biocytin and all mixtures
containing it were kept protected from light. MPB was
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brane fractions (25 μg) and purified proteins (2 μg) were
labeled in 25 μl of 10 mMK-Phosphate pH 7.4 with
100 μM of MBP. Reactions were performed for 15 min
at room temperature. Reactions were stopped by
quenching un-reacted MBP with 25 mM DTT for 5 min
at room temperature. For purified proteins, samples
were mixed with SDS-PAGE loading buffer, denatured
and separated on 12% gel SDS-PAGE. For membrane
fractions, the (His)6-proteins were extracted and purified
before analysis on SDS-PAGE and detection of the MPB
label. After quenching by DTT, membranes in 25 μl
were solubilized in 200 μl of buffer B (urea 7 M,
NaH2PO4 100 mM and Tris–HCl 20 mM pH8.0) for
20 min at room temperature. Samples were cleared by
centrifugation at 14,000 g for 5 min. The supernatant
was mixed with 50 μl of washed Ni-NTA slurry 50% and
incubated for 10 min. The resin was then washed twice
with buffer C (urea 8 M, NaH2PO4 100 mM and Tris–
HCl 20 mM pH6.3). The (His)6-protein bound to the
resin was then eluted in 50 μl buffer E (urea 8 M,
NaH2PO4 100 mM and Tris–HCl 20 mM pH4.5). This
extraction procedure was efficient and very little (His)6-
proteins were lost in the insoluble pellet or in the
washes. Eluted samples were then mixed with SDS-
PAGE loading buffer and separated on 12% gel SDS-
PAGE. When necessary, Tris–HCl 2 M pH 8.0 was used
to increase the pH of the eluted sample before loading.
After electrophoresis, proteins were transferred onto a
PVDF membrane. The blot was blocked with 1% BSA
(fraction V) in TBS with Tween-20 0.1% for 60 min at
room temperature. Hexahistidine tag of the recombinants
proteins was detected with an HRP-conjugated anti-
histidine antibody at a 1/3,000 dilution or the MPB-label
was revealed by incubation with an HRP-conjugated strepta-
vidin ligand at a 1/6,000 dilution in TBS with Tween-20
0.1% for 2 to 4 hr at room temperature. HRP detection was
performed with SuperSignal West Pico Chemiluminescent
kit (Thermo Fisher Scientific Inc., Rockford, IL).Additional files
Additional file 1: Figure S1. Acyl-transferase activity of Cysteine
substitution mutant enzymes. Mutant forms listed in Additional file 2:
Table S1 and that are not shown in Figure 6 are presented. The activity
rate of clone FK480 (Additional file 2: Table S1, row 5) and FK481
(Additional file 2: Table S1, row 4) and the effect of treatment by 1 mM
NEM and 1 mM diamide on their activity are shown in panel A.
Production of C211T C501A protein (clone FK621; Additional file 2: Table
S1, row 3) and of clone FK622 (Additional file 2: Table S1, row 16) and
FK623 (Additional file 2: Table S1, row 18) is shown in panel B. The
activity rate of the form C211T C501A was not determined but the enzyme
was active (panel C, right). Clone FK622 and FK623 do not produced
detectable amount of [14C]-PC (panel C, left). (A) Activity rate
measurements of LPCAT1, of C211T and of clone FK480 and FK481 were
performed with 5 μM [14C]-C18:1-CoA in presence of 20 μM LPC at 37°Cwith 1 μg of proteins. After separation by thin-layer chromatography (as
shown on panel C), the amount of [14C]-PC formed during the reaction
was quantified by phosphoimaging and the activity rate values are
reported as PC formed/ μg of protein per min. Values are reported
relative to the activity rate obtained with LPCAT1 enzyme. Treatment
with diamide (1 mM) and N-ethylmaleimide (1 mM) were performed for
30 min on ice before assaying acyltransferase activity. For each protein,
value obtained in absence of treatment (buffer) was set at 1 and values
obtained after treatments were calculated relative to it. Results of a
representative experiment are presented. (B) Proteins were separated on
a 12% gel SDS-PAGE and stained with coomassie blue. Molecular mass
standard (Precision Plus Protein Standard, Bio-Rad) is shown on the left.
Position of the LPCAT1 protein and of the mutant forms is indicated with
a black arrow on the left. (C) Detection of the lysoPC-acyltransferase
activity was performed with 5 μM [14C]-C18:1-CoA in presence of 20 μM
LPC at 37°C with 2 μg of proteins for 2, 4 and 6 min. Products were
separated on silica plates and detected by phosphoimaging. Position of
the un-reacted substrate [14C]-acyl-CoA and of the product [14C]-PC are
indicated.
Additional files 2: Table S1. Cysteines substitution mutants.
Additional file 3: Figure S2. Purification of LPCAT1, C211T and Cys12-
protein. Proteins were produced in E. coli and extracted from the
membrane in presence of 2% CHAPS. Then, CHAPS concentration was
decreased to 1%, and proteins were applied to a Nickel-Sepharose
column. After washing of un-bound proteins, hexa-Histidine tagged
LPCAT1 and mutant forms were eluted with imidazole concentration of
50, 200 and 500 mM, as indicated. Ten μl of samples were loaded of 12%
SDS-PAGE gel and after separation by electrophoresis, proteins were
stained with coomassie blue. Note that all three forms were partially pure
(indicated by an asterisk) in the fraction eluted by 500 mM imidazole.
Molecular mass standard is shown of the right side of the gels.
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